Solid Biosciences Phase 1/2 trial patient has serious side effects

- Patients 7 and 8 dosed in IGNITE-DMD Phase I/II clinical trial under new clinical protocol and second-generation SGT-001 manufacturing process; patient 8 experienced a serious adverse event -

- Long-term biopsy data generated from the ongoing IGNITE DMD trial demonstrate durable microdystrophin expression as measured up to two years post dosing of SGT-001. Data to be presented today at ASGCT at 1:45 PM ET -

- Continued research and innovation in musculoskeletal therapy generates next-generation DMD gene transfer candidate, SGT-003 -

- Company ends Q1 with $268.5 million in cash; cash runway into Q4 2022 -

- Company to hold conference call at 8:30am ET today -

Conference Call Information
The company will host a conference call and webcast at 8:30 a.m. ET today to discuss the program update. Participants are invited to listen by dialing +1 866-763-0341 (domestic) or +1 703-871-3818 (international) five minutes prior to the start of the call and providing the passcode 4772539. A listen-only webcast of the conference call can also be accessed through the "Investors" tab on the Solid Biosciences website, www.solidbio.com, and a replay of the call will be available for approximately six weeks after the call.

https://finance.yahoo.com/news/solid-biosciences-provides-first-quarter-113000773.html